NASDAQ:ARGX

Argenx Se Stock News

Healthcare > Biotechnology

Buy ARGX

*Your capital is at risk

$853.40

-50.35 (-5.57%)

At Close: Jun 23, 2026

argenx Eyes More VYVGART Growth as Pipeline Catalysts Near

07:07am, Friday, 12'th Jun 2026

Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflamm

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

10:15am, Wednesday, 10'th Jun 2026

Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.

ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know

09:11am, Wednesday, 10'th Jun 2026

argenx stock rises nearly 9% in a month after the FDA expands Vyvgart's gMG label, opening treatment to adult patients regardless of antibody status.

argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

01:22am, Wednesday, 10'th Jun 2026

argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

SRPT vs. ARGX: Which Stock Is the Better Value Option?

12:41pm, Monday, 08'th Jun 2026

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the bes

Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?

10:01am, Monday, 08'th Jun 2026

Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength dow

argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference

06:03am, Friday, 05'th Jun 2026

argenx NASDAQ: ARGX Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profit

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026

01:00am, Wednesday, 03'rd Jun 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren's disease indicate maintenance of response following s

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Argenx Se Stock News

argenx Eyes More VYVGART Growth as Pipeline Catalysts Near

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know

argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

SRPT vs. ARGX: Which Stock Is the Better Value Option?

Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?

argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026

argenx to Host Myositis R&D Webinar on June 23, 2026

argenx to Present at Upcoming Investor Conferences

argenx: The FcRn Franchise Is Becoming An Autoimmune Operating System

The Biology Came First.

argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

Top Fintech Company